Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1997 Jun 15;99(12):3034–3039. doi: 10.1172/JCI119499

A common mutation (G-455--> A) in the beta-fibrinogen promoter is an independent predictor of plasma fibrinogen, but not of ischemic heart disease. A study of 9,127 individuals based on the Copenhagen City Heart Study.

A Tybjaerg-Hansen 1, B Agerholm-Larsen 1, S E Humphries 1, S Abildgaard 1, P Schnohr 1, B G Nordestgaard 1
PMCID: PMC508156  PMID: 9185528

Abstract

A common mutation (G-455--> A) in the promoter region of the beta-fibrinogen gene has been associated with elevated plasma fibrinogen levels. Whether fibrinogen genotype affects plasma fibrinogen levels and risk of ischemic heart disease in the general population has not been studied. We investigated the association between fibrinogen genotype, plasma fibrinogen levels, and ischemic heart disease in a general population sample (n = 9,127). The A-allele (relative frequency, 0.20) was associated with elevated plasma fibrinogen levels in both genders (P < 0.001). While the effect of the A-allele on fibrinogen level was additive in men, the effect was dominant in postmenopausal women. The A-allele raising effect appeared to be two- to threefold greater in individuals with ischemic heart disease than in those without. An increase of 1 SD in plasma fibrinogen increased the odds ratio for ischemic heart disease by approximately 20% (P < 0.01 for women and < 0.005 for men). However, the frequency of the A-allele was similar in those with and without ischemic heart disease, and genotype was not a predictor of disease. These results demonstrate that the (G-455--> A) mutation in the promoter region of the beta-fibrinogen gene is associated with an increase in plasma fibrinogen in both genders in the general population. This increase does not appear to cause ischemic heart disease.

Full Text

The Full Text of this article is available as a PDF (215.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bara L., Nicaud V., Tiret L., Cambien F., Samama M. M. Expression of a paternal history of premature myocardial infarction on fibrinogen, factor VIIC and PAI-1 in European offspring--the EARS study. European Atherosclerosis Research Study Group. Thromb Haemost. 1994 Apr;71(4):434–440. [PubMed] [Google Scholar]
  2. Behague I., Poirier O., Nicaud V., Evans A., Arveiler D., Luc G., Cambou J. P., Scarabin P. Y., Bara L., Green F. Beta fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM Study. Etude Cas-Temoins sur l'Infarctus du Myocarde. Circulation. 1996 Feb 1;93(3):440–449. doi: 10.1161/01.cir.93.3.440. [DOI] [PubMed] [Google Scholar]
  3. Berg K., Kierulf P. DNA polymorphisms at fibrinogen loci and plasma fibrinogen concentration. Clin Genet. 1989 Oct;36(4):229–235. doi: 10.1111/j.1399-0004.1989.tb03195.x. [DOI] [PubMed] [Google Scholar]
  4. Green F., Hamsten A., Blombäck M., Humphries S. The role of beta-fibrinogen genotype in determining plasma fibrinogen levels in young survivors of myocardial infarction and healthy controls from Sweden. Thromb Haemost. 1993 Dec 20;70(6):915–920. [PubMed] [Google Scholar]
  5. Hamsten A., Iselius L., de Faire U., Blombäck M. Genetic and cultural inheritance of plasma fibrinogen concentration. Lancet. 1987 Oct 31;2(8566):988–991. doi: 10.1016/s0140-6736(87)92557-8. [DOI] [PubMed] [Google Scholar]
  6. Heinrich J., Balleisen L., Schulte H., Assmann G., van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. Arterioscler Thromb. 1994 Jan;14(1):54–59. doi: 10.1161/01.atv.14.1.54. [DOI] [PubMed] [Google Scholar]
  7. Humphries S. E., Ye S., Talmud P., Bara L., Wilhelmsen L., Tiret L. European Atherosclerosis Research Study: genotype at the fibrinogen locus (G-455-A beta-gene) is associated with differences in plasma fibrinogen levels in young men and women from different regions in Europe. Evidence for gender-genotype-environment interaction. Arterioscler Thromb Vasc Biol. 1995 Jan;15(1):96–104. doi: 10.1161/01.atv.15.1.96. [DOI] [PubMed] [Google Scholar]
  8. Kannel W. B., Wolf P. A., Castelli W. P., D'Agostino R. B. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA. 1987 Sep 4;258(9):1183–1186. [PubMed] [Google Scholar]
  9. Meade T. W., Mellows S., Brozovic M., Miller G. J., Chakrabarti R. R., North W. R., Haines A. P., Stirling Y., Imeson J. D., Thompson S. G. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet. 1986 Sep 6;2(8506):533–537. doi: 10.1016/s0140-6736(86)90111-x. [DOI] [PubMed] [Google Scholar]
  10. Montgomery H. E., Clarkson P., Nwose O. M., Mikailidis D. P., Jagroop I. A., Dollery C., Moult J., Benhizia F., Deanfield J., Jubb M. The acute rise in plasma fibrinogen concentration with exercise is influenced by the G-453-A polymorphism of the beta-fibrinogen gene. Arterioscler Thromb Vasc Biol. 1996 Mar;16(3):386–391. doi: 10.1161/01.atv.16.3.386. [DOI] [PubMed] [Google Scholar]
  11. Reed T., Tracy R. P., Fabsitz R. R. Minimal genetic influences on plasma fibrinogen level in adult males in the NHLBI twin study. Clin Genet. 1994 Feb;45(2):71–77. doi: 10.1111/j.1399-0004.1994.tb03997.x. [DOI] [PubMed] [Google Scholar]
  12. Roy S. N., Mukhopadhyay G., Redman C. M. Regulation of fibrinogen assembly. Transfection of Hep G2 cells with B beta cDNA specifically enhances synthesis of the three component chains of fibrinogen. J Biol Chem. 1990 Apr 15;265(11):6389–6393. [PubMed] [Google Scholar]
  13. Scarabin P. Y., Bara L., Ricard S., Poirier O., Cambou J. P., Arveiler D., Luc G., Evans A. E., Samama M. M., Cambien F. Genetic variation at the beta-fibrinogen locus in relation to plasma fibrinogen concentrations and risk of myocardial infarction. The ECTIM Study. Arterioscler Thromb. 1993 Jun;13(6):886–891. doi: 10.1161/01.atv.13.6.886. [DOI] [PubMed] [Google Scholar]
  14. Scarabin P. Y., Plu-Bureau G., Bara L., Bonithon-Kopp C., Guize L., Samama M. M. Haemostatic variables and menopausal status: influence of hormone replacement therapy. Thromb Haemost. 1993 Oct 18;70(4):584–587. [PubMed] [Google Scholar]
  15. Stefanick M. L., Legault C., Tracy R. P., Howard G., Kessler C. M., Lucas D. L., Bush T. L. Distribution and correlates of plasma fibrinogen in middle-aged women. Initial findings of the Postmenopausal Estrogen/Progestin Interventions (PEPI) study. Arterioscler Thromb Vasc Biol. 1995 Dec;15(12):2085–2093. doi: 10.1161/01.atv.15.12.2085. [DOI] [PubMed] [Google Scholar]
  16. Thomas A. E., Green F. R., Kelleher C. H., Wilkes H. C., Brennan P. J., Meade T. W., Humphries S. E. Variation in the promoter region of the beta fibrinogen gene is associated with plasma fibrinogen levels in smokers and non-smokers. Thromb Haemost. 1991 May 6;65(5):487–490. [PubMed] [Google Scholar]
  17. Thomas A. E., Green F. R., Lamlum H., Humphries S. E. The association of combined alpha and beta fibrinogen genotype on plasma fibrinogen levels in smokers and non-smokers. J Med Genet. 1995 Aug;32(8):585–589. doi: 10.1136/jmg.32.8.585. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Wilhelmsen L., Svärdsudd K., Korsan-Bengtsen K., Larsson B., Welin L., Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 1984 Aug 23;311(8):501–505. doi: 10.1056/NEJM198408233110804. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES